Positive Associations between Adipocyte Fatty Acid-Binding Protein Level and Central Arterial Stiffness in Peritoneal Dialysis Patients
Table 1
Clinical variable of the 76 peritoneal dialysis patients with or without arterial stiffness.
Characteristic
All participants (n = 76)
Control group (n = 51)
Arterial stiffness group (n = 25)
value
Age (years)
55.51 ± 15.91
51.61 ± 16.12
63.48 ± 12.32
0.002
Peritoneal dialysis vintage (months)
50.83 ± 40.73
42.39 ± 37.74
68.04 ± 41.90
0.009
Height (cm)
160.04 ± 8.31
160.76 ± 8.24
158.56 ± 8.42
0.280
Body weight (kg)
63.18 ± 14.76
62.45 ± 13.16
64.66 ± 17.79
0.543
Body mass index (kg/m2)
24.70 ± 4.52
24.30 ± 4.16
25.51 ± 5.20
0.277
Carotid-femoral PWV (m/s)
9.26 ± 3.23
7.39 ± 1.67
13.08 ± 2.05
<0.001
Systolic blood pressure (mmHg)
143.03 ± 23.76
139.90 ± 24.75
149.40 ± 20.62
0.102
Diastolic blood pressure (mmHg)
84.50 ± 12.50
82.84 ± 12.99
87.88 ± 10.92
0.099
Total cholesterol (mg/dL)
169.08 ± 39.17
167.37 ± 37.67
172.56 ± 42.64
0.591
Triglyceride (mg/dL)
143.00 (93.75–222.25)
136.00 (91.00–209.00)
159.00 (108.00–231.00)
0.490
Fasting glucose (mg/dL)
106.00 (95.00–129.25)
102.00 (91.00–122.00)
117.00 (100.00–165.50)
0.012
Albumin (mg/dL)
3.72 ± 0.38
3.74 ± 0.42
3.69 ± 0.29
0.536
Blood urea nitrogen (mg/dL)
59.03 ± 18.43
59.31 ± 18.55
58.44 ± 18.54
0.848
Creatinine (mg/dL)
11.08 ± 3.14
11.12 ± 3.36
10.99 ± 2.71
0.876
Total calcium (mg/dL)
9.10 ± 0.77
9.07 ± 0.71
9.16 ± 0.90
0.637
Phosphorus (mg/dL)
5.23 ± 1.41
5.28 ± 1.46
5.12 ± 1.35
0.650
Intact parathyroid hormone (pg/mL)
247.16 (120.20–558.10)
266.55 (113.37–565.65)
229.20 (111.71–503.42)
0.822
C-reactive protein (mg/dL)
0.26 (0.07–0.91)
0.13 (0.06–0.53)
0.36 (0.26–1.36)
0.001
A-FABP (ng/mL)
53.55 ± 28.07
44.42 ± 22.01
72.17 ± 30.26
<0.001
Weekly (Kt/V)
2.09 ± 0.41
2.15 ± 0.44
1.97 ± 0.32
0.085
Peritoneal (Kt/V)
1.75 ± 0.47
1.75 ± 0.48
1.73 ± 0.46
0.845
Total clearance of creatinine (L/week)
59.26 ± 23.98
61.18 ± 26.10
55.34 ± 18.82
0.322
Peritoneal clearance of creatinine (L/week)
41.79 ± 16.10
41.34 ± 16.36
42.71 ± 15.83
0.729
Female, n (%)
44 (57.9)
31 (60.8)
13 (52.0)
0.466
Diabetes, n (%)
32 (42.1)
20 (39.2)
12 (48.0)
0.466
Hypertension, n (%)
65 (85.5)
43 (84.3)
22 (88.0)
0.668
CAPD, n (%)
56 (73.7)
36 (70.6)
20 (80.0)
0.381
ACE inhibitor use, n (%)
5 (6.6)
4 (7.8)
1 (4.0)
0.525
ARB use, n (%)
32 (42.1)
23 (45.1)
9 (36.0)
0.450
β-blocker use, n (%)
28 (36.8)
21 (41.2)
7 (28.0)
0.263
CCB use, n (%)
35 (46.1)
24 (47.1)
11 (44.0)
0.802
Statin use, n (%)
20 (26.3)
14 (27.5)
6 (24.0)
0.748
Fibrate use, n (%)
3 (3.9)
2 (8.0)
1 (2.0)
0.204
Values for continuous variables are shown as mean ± standard deviation after analysis by Student's t test; variables not normally distributed are shown as median and interquartile range after analysis by the Mann–Whitney U test; values are presented as number (%) and analysis after analysis by the chi-squared test. A-FABP, adipocyte fatty acid binding protein; CAPD, continuous ambulatory peritoneal dialysis; weekly Kt/V, weekly fractional clearance index for urea; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker. < 0.05 was considered statistically significant.
